The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus

Epilepsy and Behavior

Volumn 49, Issue , 2015, Pages 298-302

  Shekh Ahmad, Tawfeeq ^a   Mawasi, Hafiz ^a   McDonough, John H ^b   Yagen, Boris ^a   Bialer, Meir ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

Benzodiazepine resistant status epilepticus; Chiral switch; New antiepileptic drugs; Stereoselective pharmacokinetic and pharmacodynamic analysis

Indexed keywords

2,3 SEC BUTYLPROPYLACETAMIDE; 2,3 VALNOCTAMIDE; ANTICONVULSIVE AGENT; CENTRAL DEPRESSANT AGENT; SEC BUTYLPROPYLACETAMIDE; UNCLASSIFIED DRUG; VALNOCTAMIDE; AMIDE; SEC-BUTYL-PROPYLACETAMIDE; VALPROIC ACID;

ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; EPILEPSY; EPILEPTIC STATE; HUMAN; NEUROTOXICITY; NONHUMAN; RACEMIC MIXTURE; RODENT MODEL; SEIZURE; STEREOCHEMISTRY; STEREOISOMERISM; TERATOGENICITY; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; STATUS EPILEPTICUS;

AMIDES; ANIMALS; ANTICONVULSANTS; HUMANS; STATUS EPILEPTICUS; STEREOISOMERISM; VALPROIC ACID;

EID: 84938953746     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2015.04.012     Document Type: Article

References (20)

1. Barel S., Yagen B., Schurig V., Soback S., Pisani F., Perucca E., et al. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and epileptic patients. Clin Pharmacol Ther 1997, 61:442-449.
2. Bialer M., Yagen B. Valproic acid - second generation. Neurotherapeutics 2007, 4:130-137.
3. Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 2012, 64:887-895.
4. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010, 92:89-124.
5. Bialer M., White H.S. Key factors in the discovery and development of new antiepileptic drugs (AEDs). Nat Rev Drug Discov 2010, 9:68-83.
6. White H.S., Alex A.B., Pollock A., Hen N., Shekh-Ahmed T., Wilcox K.S., et al. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 2012, 53:134-146.
7. Pouliot W., Bialer M., Hen N., Shekh-Ahmad T., Kaufmann D., Yagen B., et al. A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Neuroscience 2013, 231:145-156.
8. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013, 103:2-30.
9. Bialer M., Johannessen S.I., Levy R.H., Perucca E., Tomson T., White H.S. Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res 2015, 111:85-141.
10. Shekh-Ahmad T., Hen N., McDonough J.H., Yagen B., Bialer M. Valnoctamide and sec-propyl-butylacetamide (SPD) for acute seizures and status epilepticus. Epilepsia 2013, (Suppl. 5):98-101.
11. Hen N., Shekh-Ahmad T., Yagen B., McDonough J.H., Finnell R.H., Wlodarczyk B., et al. Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. J Med Chem 2013, 56:6467-6477.
12. Shekh-Ahmad T., Hen N., Yagen B., McDonough J.H., Finnell R.H., Wlodarczyk B., et al. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia 2014, 55:353-361.
13. Bar-Klein G., Swissa E., Kamintsky L., Shekh-Ahmad T., Hubary Y., Shrot S.L., et al. sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats. Epilepsia 2014, 55:1953-1958.
14. Tjolsen A., Berge O.-G., Hunskaar J., Roseland H.R., Hole K. The formalin test: an evaluation of the method. Pain 1992, 51:5-17.
15. Kaufmann D., Yagen B., Minert A., Wlodarczyk B., Finnell R., Schrig V., et al. Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Neuropharmacology 2010, 52:1228-1236.
16. Spampanato J., Dudek E.F. Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus. Epilepsia 2014, 55:e94-e98.
17. Meador K.J., Baker G.A., Browning N., Clayton-Smith J., Combs-Cantrell D.T., Cohen M., et al. Cognitive function at 3years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-1605.
18. Tomson T., Battino D., Bonizzoni E., Craig J., Lindhout D., Sabers A., et al. EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011, (10):609-6017.
19. European Medicines Agency (EMA) website:. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_detail_002186.jsp&mid=WC0b01ac058004d5c1.
20. Bialer New antiepileptic drugs (AEDs) in clinical development which are second generation to existing AEDs. Expert Opin Investig Drugs 2006, 15:637-647.